Use of amyloid PET across the spectrum of Alzheimer's disease: Clinical utility and associated ethical issues

Amyloid

Volumn 21, Issue 3, 2014, Pages 143-148

  Leuzy, Antoine ^a,b   Zimmer, Eduardo Rigon ^a,b,c   Heurling, Kerstin ^d   Rosa Neto, Pedro ^a,b   Gauthier, Serge ^b  

^a DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Appropriate use criteria; Diagnosis; Mild cognitive impairment; Positron emission tomography

Indexed keywords

AMYLOID; FLORBETABEN; FLORBETAPIR F 18; FLUTEMETAMOL F 18; PITTSBURGH COMPOUND B; AMYLOID BETA PROTEIN; ANILINE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; CARBON; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; FLUORINE; FLUTEMETAMOL; N-METHYL-2-(4'-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE; RADIOPHARMACEUTICAL AGENT;

ALZHEIMER DISEASE; COST EFFECTIVENESS ANALYSIS; DEMENTIA; HUMAN; MILD COGNITIVE IMPAIRMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; ASYMPTOMATIC DISEASE; BRAIN; DIAGNOSTIC USE; ETHICS; METABOLISM; PATHOLOGY; SCINTISCANNING; UTILIZATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; ASYMPTOMATIC DISEASES; BENZOTHIAZOLES; BRAIN; CARBON RADIOISOTOPES; DEMENTIA; ETHYLENE GLYCOLS; FLUORINE RADIOISOTOPES; HUMANS; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84906228305     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2014.926267     Document Type: Review

References (61)

1. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement 2013;9:1-15.
2. Soucy JP, Bartha R, Bocti C, Borrie M, Burhan AM, Laforce Jr. R, Rosa-Neto, P. Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther 2013;5:1-11.
3. Rowe CC, Villemagne VL. Amyloid imaging with PET in early Alzheimer disease diagnosis. Med Clin North Am 2013;97: 377-98.
4. Cohen AD, Rabinovici GD, Mathis CA, Jagust WJ, Klunk WE, Ikonomovic MD. Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol 2012;64: 27-81.
5. Wolk DA, Grachev ID, Buckley C, Kazi H, Grady MS, Trojanowski JQ, Hamilton RH, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 2011;68:1398-403.
6. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, Fleisher AS, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 2012;11:669-78.
7. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, Tochoy-Danguy H, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129-35.
8. Vallabhajosula S. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid. Semin Nucl Med 2011;41: 283-99.
9. Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med Technol 2013;41:11-8.
10. U.S. Food and Drug Administration. FDA approves imaging drug Amyvid: estimates brain amyloid plaque content in patients with cognitive decline. 2012 Apr 10. Available from: http:// www.fda.gov/newsevents/newsroom/ pressannouncements/ucm 299678.htm [last accessed 1 Dec 2013].
11. European Medicines Agency. Amyvid: florbetapir (18F). 2013 Jan 23. Available from: http://www.ema.europa.eu/ema/index.jsp?- curl=pages/medicines/ human/medicines/002422/human-med- 001611.jsp&mid=WC0b01ac058001d124 [last accessed 16 Apr 2014].
12. Piramal Group. FDA Approves Piramal Imaging's Neuraceq (florbetaben F18 injection) for PET Imaging of Beta-Amyloid Neuritic Plaques in the Brain. 2014 Mar 20. Available from: http://www.prnewswire.com/news-releases/fdaapproves- piramal-imagings-neuraceq-florbetaben-f18-injectionfor- pet-imaging-of-beta- amyloid-neuritic-plaques-in-the-brain- 251216031.html [last accessed 16 Apr 2014].
13. European Medicines Agency. Neuraceq: florbetaben (18F) Amyvid: florbetapir (18F). 2014 Mar 11. Available from: http:// www.ema.europa.eu/ema/ index.jsp?curl=pages/medicines/human/ medicines/002553/human-med-001716. jsp&mid=WC0b01ac 058001d124 [last accessed 16 Apr 2014].
14. U.S. Food and Drug Administration. FDA Approves a Second Amyloid Imaging Agent. 2013 Nov 21. Available from: http://www.fda.gov/newsevents/newsroom/ pressannouncements/ ucm299678.htm [last accessed 16 Apr 2014].
15. Cselenyi Z, Jönhagen ME, Forsberg A, Halldin C, Julin P, Schou M, Johnström P, et al. Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand. J Nucl Med 2012;53: 415-24.
16. Jureus A, Swahn BM, Sandell J, Jeppsson F, Johnson AE, Johnström P, Neelissen JA, et al. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem 2010;114:784-94.
17. Zimmer E, Parent M, Leuzy A, Rowley J, Cheewakriengkrai L, Shin M, Wang S, et al. [18F]NAV4694 shows higher binding and wider dynamic range compared with [11C]PiB in Alzheimer's disease postmortem tissue. Alzheimers Dement 2013;9:P584.
18. Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, Cselényi Z, et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. J Nucl Med 2013;54:880-6.
19. Vandenberghe R, Van Laere K, lvanoiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010;68:319-29.
20. Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-S positron emission tomography. J Neurol Neurosurg Psychiatry 2012;83:923-6.
21. Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O'Keefe G, Chan JG, et al. Comparison of 11C-PiB and 18F-Horbetaben for A beta imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012;39:983-9.
22. Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, Mintun MA, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 2013;54:70-7.
23. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-8. (Pubitemid 29120227)
24. Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia 2000;15:93-101. (Pubitemid 30340226)
25. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr. CR, Kawas CH, Klunk WE, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7: 263-9.
26. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718-25. (Pubitemid 46763260)
27. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008;115:409-15.
28. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67:446-52. (Pubitemid 44214969)
29. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Kiolko SK, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509-17.
30. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31:1275-83.
31. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006;66:1837-44. (Pubitemid 44049813)
32. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007;130:2837-44. (Pubitemid 350033975)
33. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7: 280-92.
34. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367:795-804.
35. Desikan RS, McEvoy LK, Thompson WK, Holland D, Brewer JB, Aisen PS, Sperling RA, et al. Amyloid-beta-associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol 2012;69:709-13.
36. Knopman DS, Jack Jr. CR, Wiste HJ, Weigand SD, Vemuri P, Lowe V, Kantarci K, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012;78: 1576-82.
37. Alzheimer's Disease Cooperative Study. Anti-Amyloid treatment of Asymptomatic AD - The A4 Trial. Available from: http:// www.adcs.org/Studies/A4. aspx [last accessed 4 Dec 2013].
38. Shulman MB, Harkins K, Green RC, Karlawish J. Using AD biomarker research results for clinical care: a survey of ADNI investigators. Neurology 2013;81:1114-21.
39. Bredenoord A, Kroes H, Cuppen E, Parker M, van Delden JJ. Disclosure of individual genetic data to research participants: the debate reconsidered. Trends Genet 2014;27:41-7.
40. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-9.
41. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-46. (Pubitemid 47058377)
42. Gauthier S, Rosa-Neto P. Dementia: disclosure of results to participants in dementia research. Nat Rev Neurol 2013;9: 608-9.
43. Shalowitz DI, Miller FG. Communicating the results of clinical research to participants: attitudes, practices, and future directions. PLoS Med 2008;5:e91.
44. Broadstock M, Michie S, Marteau T. Psychological consequences of predictive genetic testing: a systematic review. Eur J Hum Genet 2000;8:731-8.
45. Partridge AH, Wong JS, Knudsen K, Gelman R, Sampson E, Gadd M, Bishop KL, et al. Offering participants results of a clinical trial: sharing results of a negative study. Lancet 2005;365: 963-4. (Pubitemid 41071430)
46. Smith CO, Lipe HP, Bird TD. Impact of presymptomatic genetic testing for hereditary ataxia and neuromuscular disorders. Arch Neurol 2004;61:875-80. (Pubitemid 38747326)
47. Steinbart EJ, Smith CO, Poorkaj P, Bird TD. Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia. Arch Neurol 2001;58:1828-31. (Pubitemid 33044250)
48. Karlawish J. Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. Neurology 2011;77:1487-93.
49. Lingler JH, Klunk WE. Disclosure of amyloid imaging results to research participants: has the time come? Alzheimers Dement 2013;9:741-4 e2.
50. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, Bullock R, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009;73:754-60.
51. Laforce Jr. R, Rabinovici GD. Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther 2011;3:31.
52. Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, Agarwal N, Mormino EC, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011;77: 2034-42.
53. Vandenberghe R, Adamczuk K, Dupont P, Laere KV, Chételat G. Amyloid PET in clinical practice: its place in the multidimensional space of Alzheimer's disease. Neuroimage Clin 2013;2:497-511.
54. Klein EP, Kaye J. Dementia specialists and early adoption of amyloid imaging. J Alzheimers Dis 2013;33:445-50.
55. Blendon RJ, Benson JM, Wikler EM, Weldon KJ, Georges J, Baumgart M, Kallmyer BA. The Impact of Experience with a Family Member with Alzheimer's Disease on Views about the Disease across Five Countries. Int J Alzheimers Dis 2012;2012:1-9.
56. Jagust WJ. Amyloid imaging: liberal or conservative? Let the data decide. Arch Neurol 2011;68:1377-8.
57. GE Healthcare. New [18F]Flutemetamol Data Presented by GE Healthcare at 7th Annual Human Amyloid Imaging Conference. 2013 Jan 28. Available from: http://www.businesswire.com/news/ home/20130118005505/en/18F-Flutemetamol-Data- Presented-GEHealthcare- 7th#.U07NQ61dWxR [last accessed 16 Apr 2014].
58. Seibyl J, Barthel H, Stephens A, Reininger C, Sabri O. Reliability, reproducibility and efficacy of the 18F florbetaben b-amyloid PET scan visual assessment method as trained via a computerbased instructional tool. J Nucl Med [Internet]. 2013;54:300. Available from: http://jnumedmtg.snmjournals.org/cgi/ content/ meeting-abstract/54/2-MeetingAbstracts/300 [last accessed 16 Apr 2014].
59. Ishii K. PET Approaches for Diagnosis of Dementia. AJNR Am J Neuroradiol 2013. In press 2014.
60. Jagust WJ. Amyloid imaging: coming to a PET scanner near you. Ann Neurol 2010;68:277-8.
61. Lerner AJ. Amyloid imaging: the court of public opinion. Neurology 2013;81:1108-9.